Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia

29 de abril de 2026 atualizado por: Shanghai East Hospital

High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia: Adaptive Platform Study

The study aims to find a better surgical treatment for men with an enlarged prostate (Benign Prostatic Hyperplasia, or BPH) that effectively relieves urinary symptoms without sacrificing sexual function.

Currently, standard surgeries like TURP or HoLEP are very effective at opening the blocked urinary channel. However, because they use heat or mechanical energy to remove prostate tissue, they often cause unwanted side effects, most notably the loss of normal ejaculation (retrograde ejaculation) and potential impacts on erectile function.

This study is testing a novel, minimally invasive technology called High-Frequency Irreversible Electroporation (H-FIRE). Instead of using heat to burn or cut the tissue, H-FIRE delivers ultra-short electrical pulses to destroy the blocking prostate tissue. This "non-thermal" (heat-free) approach is uniquely designed to spare the delicate nerves, blood vessels, and muscles surrounding the prostate, which are critical for preserving normal sexual function and bladder control.

In this clinical trial, 288 men aged 50 and older with moderate-to-severe BPH symptoms will be randomly assigned to receive either the investigational H-FIRE procedure or the Standard of Care surgery (TURP or HoLEP).

The main goal of the study is to prove that H-FIRE is just as effective as standard surgery in relieving lower urinary tract symptoms over 12 months. More importantly, the study will evaluate if H-FIRE is superior in helping patients achieve the "BPH Trifecta"-meaning the patient successfully achieves significant symptom relief, maintains perfect bladder control (uses zero pads), AND fully preserves normal ejaculation.

By utilizing this new tissue-sparing technology, the trial hopes to offer aging men a treatment option that restores their urinary health while fully protecting their overall quality of life.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

288

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Shanghai East hospital ethics committee
  • Número de telefone: +86-021-38804518
  • E-mail: siwei_bao@163.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Moderate-to-severe symptoms, defined as IPSS ≥13. Prostate volume (PV) between 30 and 150 ml, measured by multi-parametric MRI (mpMRI) or Transrectal Ultrasound (TRUS).

Maximum urinary flow rate (Qmax) ≤15 ml/s. Note: To ensure validity, the voided volume during uroflowmetry must be ≥125 ml; tests with lower volumes must be repeated.

Competency to provide informed consent and comply with long-term follow-up.

Exclusion Criteria:

Suspected or histologically confirmed prostate cancer. Patients with PSA >4 ng/ml must undergo mpMRI; those with PI-RADS ≥3 lesions require a negative biopsy before enrolment.

Neurogenic bladder, detrusor underactivity, or active urinary tract infection (UTI).

Previous prostate surgery, pelvic irradiation, urethral stricture, or bladder neck contracture.

Presence of metallic implants incompatible with H-FIRE pulse delivery (e.g., non-compatible pacemakers).

Inability to safely discontinue anticoagulation if required by the assigned surgical protocol.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: H-FIRE
Participants randomized to this arm will undergo High-Frequency Irreversible Electroporation (H-FIRE). The procedure is performed under general anesthesia with deep neuromuscular blockade. Using transrectal ultrasound (TRUS) guidance and a transperineal template, electrodes are positioned to bracket the transition zone. The H-FIRE generator delivers microsecond-pulsed electric fields to induce non-thermal apoptosis of the obstructing prostatic adenoma. To maintain the PROBE (Prospective Randomized Open-label Blinded-Endpoint) design and keep outcome assessors blinded to the surgical approach, all participants in this arm will also receive a sham perineal dressing for 3 days and continuous bladder irrigation for at least 24 hours post-procedure.
Procedimento: H-FIRE
High-Frequency Irreversible Electroporation (H-FIRE) is a novel, non-thermal, tissue-selective ablation technique. Under transrectal ultrasound (TRUS) guidance, 19-gauge monopolar electrodes are inserted transperineally via a template to bracket the prostatic transition zone. The H-FIRE generator delivers ultrashort bursts of high-voltage microsecond-pulsed electric fields . This rapidly destabilizes the transmembrane potential, creating permanent nanoscale pores in the cell membrane and inducing cellular apoptosis rather than coagulative necrosis. This unique non-thermal mechanism is designed to effectively ablate obstructing prostatic adenoma while sparing the collagenous architecture of neurovascular bundles and the external sphincter.
Comparador Ativo: Shared Control Arm: Standard of Care
Participants randomized to this arm will receive the surgical Standard of Care (SoC), stratified by baseline prostate volume. For prostates 30-80 mL, surgeons will perform either Transurethral Resection of the Prostate (TURP) or Holmium Laser Enucleation of the Prostate (HoLEP). For prostates >80-150 mL, HoLEP is mandated. Procedures aim for complete anatomical removal of the obstructing adenoma. To maintain the PROBE (Prospective Randomized Open-label Blinded-Endpoint) design and mask the transurethral approach from blinded outcome assessors, all participants in this arm will also receive a sham perineal dressing for 3 days and continuous bladder irrigation for at least 24 hours post-procedure.
Procedimento: Surgical Standard of Care (TURP or HoLEP)
The Standard of Care (SoC) intervention comprises guideline-endorsed transurethral surgical procedures for benign prostatic obstruction. The specific surgical modality is strictly mandated by baseline prostate volume stratification to ensure optimal therapeutic efficacy. For prostates measuring 30 to 80 mL, surgeons perform either Transurethral Resection of the Prostate (TURP, Monopolar or Bipolar) or Holmium Laser Enucleation of the Prostate (HoLEP). For larger prostates (>80 to 150 mL), HoLEP is strictly mandated. Both procedures are performed under anesthesia with the clinical goal of achieving complete anatomical removal of the obstructing adenoma (resection to the surgical capsule for TURP, or anatomical enucleation for HoLEP).

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in International Prostate Symptom Score (IPSS)
Prazo: Baseline and 12 months
The IPSS is a validated 7-item questionnaire assessing lower urinary tract symptoms. The total score ranges from 0 to 35. Higher scores indicate more severe symptoms (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic). A decrease in the score indicates symptomatic improvement.
Baseline and 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of Participants Achieving the "BPH Trifecta"
Prazo: 1,3,6,12 months
The "BPH Trifecta" is a composite success endpoint defined as the simultaneous achievement of three criteria: (i) Effective de-obstruction (IPSS reduction >=50% from baseline or total score <8); (ii) Social Continence (0 pads/day); and (iii) Preservation of Ejaculation (MSHQ-EjD Function Score >=2).
1,3,6,12 months
Change from Baseline in International Index of Erectile Function (IIEF-5) Score
Prazo: Baseline, 1, 3, 6, and 12 months
The IIEF-5 is a validated questionnaire assessing erectile dysfunction. Total scores range from 1 to 25. Higher scores indicate better erectile function and lesser severity of dysfunction.
Baseline, 1, 3, 6, and 12 months
Change from Baseline in Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) Short Form Score
Prazo: Baseline, 1, 3, 6, and 12 months
The MSHQ-EjD Short Form assesses ejaculatory function. The function domain score ranges from 1 to 15. Higher scores indicate better ejaculatory function (greater frequency, strength, and volume).
Baseline, 1, 3, 6, and 12 months
Change from Baseline in Maximum Urinary Flow Rate (Qmax)
Prazo: Baseline, 1, 3, 6, and 12 months
Maximum urinary flow rate (Qmax) evaluated via uroflowmetry. Assessed with a minimum voided volume requirement of 125 mL. Higher values indicate better urinary flow and less obstruction.
Baseline, 1, 3, 6, and 12 months
Change from Baseline in Post-Void Residual (PVR) Urine Volume
Prazo: Baseline, 1, 3, 6, and 12 months
Post-void residual (PVR) urine volume measured via transabdominal ultrasound immediately after a voluntary void. Lower values indicate better bladder emptying.
Baseline, 1, 3, 6, and 12 months
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Prazo: Up to 12 months post-procedure
Adverse events will be systematically recorded and graded. Surgical complications will be classified using the Clavien-Dindo Classification system. General medical adverse events and genitourinary symptoms will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Key Adverse Events of Special Interest (AESI) include urethral stricture, transient/permanent incontinence, and retrograde ejaculation.
Up to 12 months post-procedure
Incremental Cost-Effectiveness Ratio (ICER)
Prazo: 12 months
The ICER will be calculated from a societal perspective as the incremental cost per Quality-Adjusted Life Year (QALY) gained. QALYs will be derived from the EQ-5D-5L utility index scores. Lower ICER values indicate a more cost-effective intervention.
12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Shanghai East Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

5 de maio de 2026

Conclusão Primária (Estimado)

5 de maio de 2028

Conclusão do estudo (Estimado)

5 de maio de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

29 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de abril de 2026

Primeira postagem (Real)

7 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

7 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de abril de 2026

Última verificação

1 de março de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2026056

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em HBP

Ensaios clínicos em H-FIRE

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Iran

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever